Top in endocrinology: Tirzepatide improves sleep apnea; updated prolactinomas guidance
Click Here to Manage Email Alerts
Tirzepatide improved obstructive sleep apnea symptoms compared with placebo among adults with obesity, according to results from the SURMOUNT-OSA trials.
After 1 year of treatment, patients receiving tirzepatide (Zepbound, Eli Lilly) had 27.4 fewer events per hour on the apnea-hypopnea index, while patients receiving placebo had 4.8 fewer events per hour. It was the top story in endocrinology last week.
Another top story was about an international consensus statement from The Pituitary Society about the diagnosis and management of prolactinomas. The statement is the first guideline on prolactinomas to be published since 2011.
Read these and more top stories in endocrinology below:
Tirzepatide improves sleep apnea symptoms for adults with OSA plus obesity
Adults with moderate to severe obstructive sleep apnea and obesity had reductions in sleep apnea severity at 1 year with 10 mg or 15 mg of tirzepatide, according to topline results from two phase 3 trials. Read more.
New consensus statement addresses advances in diagnosing, managing prolactinomas
The way endocrinologists manage prolactinomas is changing. A new international consensus statement from The Pituitary Society incorporates recent evidence on possible newly recognized adverse events associated with dopamine agonists, efficacy of transsphenoidal surgery and treatment of special populations, such as pregnant women and transgender adults. Read more.
Gut microbiome composition may alter risk for obesity
Some changes in gut microbiome composition may increase the risk for obesity, with those changes affecting men and women differently, according to data that will be presented at the European Congress on Obesity. Read more.
Task force recommends population-based tool to better assess fracture risk in US
The use of racial-ethnic adjustments in the U.S. version of the Fracture Risk Assessment Tool may be underestimating fractures among underrepresented groups, and new, more accurate tools are needed, according to a task force report. Read more.
Q&A: Standards of Care encourages more people with diabetes to use CGM
The 2024 American Diabetes Association Standards of Care put an emphasis on getting continuous glucose monitoring into the hands of more people with diabetes. Read more.